Catalog3 refs
PT-141
ReproductivetherapeuticSexual HealthResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Circulation
Overview
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist derived from melanotan II. It is FDA-approved under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike PDE5 inhibitors, PT-141 works centrally through the nervous system rather than directly on blood vessels, making it the first FDA-approved medication that targets desire rather than physical arousal.
Primary Uses
Hypoactive sexual desire disorder (HSDD) in premenopausal women
Erectile dysfunction in men (including those unresponsive to PDE-5 inhibitors)
Enhancement of sexual desire and arousal
Reduction of distress associated with low sexual desire
Treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women
Increasing sexual desire and motivation via central nervous system mechanism
Hypoactive sexual desire studies
Melanocortin receptor pharmacology
Female sexual function
Arousal signaling
Erectile dysfunction
Hypoactive Sexual Desire Disorder (HSDD)
Female Sexual Arousal Disorder
Sexual Distress Reduction
Sexual Satisfaction
Hypoactive sexual desire disorder
Increased sexual desire
Off-label use for low libido in men
Off-label use for erectile dysfunction in men
Protocol Reference
Dose
200–500 mcg as needed, start at lower end)
Frequency
As Needed
Half-life
~2.7 Hours
Route
Subcutaneous
Evidence
Human Clinical Data Available / Phase 4, FDA Approved / FDA-approved / FDA Approved / FDA approved (disputed)
Research References· 20
Research Models
HumanMouseRat
Also in Reproductive